^
Association details:
| Biomarker: | TMB-L |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + cabiralizumab (BMS-986227) (CSF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
Published date:
05/16/2018
Excerpt:
PD activity of cabira + NIVO in pts with advanced tumors treated in a ph 1a/b trial (NCT02526017) was evaluated using peripheral and tumor biomarkers….Of note, in the 4 PRs observed in pts with pancreatic cancer, all were microsatellite stable (MSS) and low TMB.
DOI:
10.1200/JCO.2018.36.15_suppl.3020
Trial ID:
